CDK4 and Familial prostate cancer: Therefore, our findings not only illustrate the molecular mechanism of BET inhibitor resistance caused by RB loss, but also reveal a potential therapeutic strategy for prostate cancers with abnormalities in RB, CDK4/6, and/or CREB signaling.